Condition
Epithelial Cancer Patients
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Enrolling By Invitation1
Terminated1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07644403Phase 1Enrolling By InvitationPrimary
Phase I/IIa Clinical Trial of IMC001 in Patients With Advanced Epithelial Solid Tumors.
NCT01320020Phase 1TerminatedPrimary
A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Showing all 2 trials